Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-19 06:28Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is located in Futian District, Shenzhen, Guangdong Province, and was established on November 3, 1998. The company was listed on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1]. - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1]. Stock Performance - On September 19, Xinlitai's stock fell by 5.14%, closing at 51.70 CNY per share, with a trading volume of 301 million CNY and a turnover rate of 0.51%. The total market capitalization is 57.636 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Chuangjin Hexin has a significant position in Xinlitai. The Chuangjin Hexin Health Mixed A Fund (013348) reduced its holdings by 22,500 shares in the second quarter, holding a total of 138,500 shares, which represents 5.99% of the fund's net value, ranking as the ninth largest holding [2]. - The Chuangjin Hexin Health Mixed A Fund was established on January 26, 2022, with a latest scale of 40.2061 million CNY. Year-to-date returns are 48.83%, ranking 1032 out of 8172 in its category, while the one-year return is 53.87%, ranking 2857 out of 7980. Since its inception, the fund has experienced a loss of 15.48% [2]. Fund Manager Information - The fund manager of Chuangjin Hexin Health Mixed A Fund is Pi Jinsong, who has been in the position for 6 years and 326 days. The total asset size of the fund is 621 million CNY. During his tenure, the best fund return was 130.01%, while the worst return was -49.36% [3].